Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500mg, 750mg and 1000mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP)
- 30 November 2004
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 24 (5) , 479-484
- https://doi.org/10.1016/j.ijantimicag.2004.06.010
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment ParadigmClinical Infectious Diseases, 2003
- A Critical Review of the FluoroquinolonesDrugs, 2002
- LevofloxacinDrugs, 2002
- Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on EradicationAntimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract InfectionsAntimicrobial Agents and Chemotherapy, 2001
- Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infectionsCurrent Opinion in Pharmacology, 2001
- Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756Antimicrobial Agents and Chemotherapy, 2000
- Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysisJAMA, 1996
- Principles of Good Practice for the Use of Monte Carlo Techniques in Human Health and Ecological Risk AssessmentsRisk Analysis, 1994
- Monte Carlo Techniques for Quantitative Uncertainty Analysis in Public Health Risk AssessmentsRisk Analysis, 1992